Proposed Section Structure
Highlights
Background and Disease Burden
Study Design and Data Source
Key Findings
Clinical Interpretation and Public Health Relevance
Strengths and Limitations
Conclusion
Funding and Registration
References
Highlights
Status epilepticus-related mortality in U.S. adults aged 25 years and older did not decline over the last two decades; instead, age-adjusted mortality was stable until 2007 and then rose through 2020.
The mortality burden was concentrated in clinically recognizable high-risk groups: adults aged 65 years and older, men, and people identified as Non-Hispanic Black.
Geographic disparities were substantial, with the South showing the highest age-adjusted mortality rate among U.S. census regions.
Most deaths occurred in medical facilities, underscoring that status epilepticus remains a lethal emergency despite contemporary hospital-based care.
Background and Disease Burden
Status epilepticus (SE) is one of the most time-sensitive neurologic emergencies in adult medicine. Traditionally defined as prolonged seizure activity or recurrent seizures without return to baseline, SE is now approached clinically as a condition requiring immediate treatment once a generalized convulsive seizure persists beyond several minutes. Delays in recognition and treatment are associated with neuronal injury, systemic complications, refractoriness to antiseizure therapy, and death.
For clinicians, the importance of SE extends beyond its acute management algorithm. Mortality is influenced not only by seizure control itself, but also by the underlying cause, age, physiologic reserve, comorbid illness, access to emergency care, and complications such as aspiration, respiratory failure, stroke, central nervous system infection, or metabolic derangement. In older adults, SE often occurs in the setting of cerebrovascular disease or systemic illness and carries especially poor outcomes. In hospital practice, mortality may be driven as much by the precipitating disorder as by ongoing electroclinical seizure activity.
Against that backdrop, understanding population-level mortality trends is clinically relevant. If deaths are rising despite advances in emergency neurologic care, the likely explanation is multifactorial: aging of the population, changes in case ascertainment, increasing burden of chronic neurologic and vascular disease, persistent inequities in care delivery, or variation in prehospital and inpatient management. The present study addresses these questions using national mortality data, with emphasis on temporal patterns and disparities by age, sex, race/ethnicity, and geography.
Study Design and Data Source
Nadeem and colleagues conducted a retrospective mortality study using the CDC WONDER database, a well-established U.S. source for death certificate-based mortality surveillance. The analysis included adults aged 25 years or older from 1999 through 2020. The investigators calculated crude mortality rates (CRs) and age-adjusted mortality rates (AAMRs) per 100,000 persons.
Age adjustment is especially important in a condition like SE because mortality risk rises sharply with age; comparing crude rates alone across populations can therefore be misleading. To evaluate how mortality changed over time, the authors used joinpoint regression to estimate annual percent change (APC), a standard epidemiologic method for identifying shifts in trend trajectories.
The main outcomes were temporal changes in SE-related mortality and differences in mortality by age group, sex, race/ethnicity, and U.S. region. This is a descriptive epidemiologic study rather than an interventional trial, so it cannot establish causality. However, it is well suited to identifying high-burden populations and informing both health services research and targeted policy responses.
Key Findings
From 1999 to 2020, the investigators identified 32,174 deaths related to status epilepticus among U.S. adults aged 25 years or older. Notably, 83.7% of these deaths occurred in medical facilities. That proportion is clinically telling. It suggests that most fatal SE events reached the healthcare system, meaning mortality cannot be attributed simply to failure of access to any care at all. Instead, the findings raise broader questions about disease severity at presentation, timeliness of treatment, ICU resources, underlying etiologies, and post-acute complications.
Temporal trend
The most important longitudinal observation was a biphasic pattern. The national age-adjusted mortality rate remained relatively stable from 1999 to 2007, then increased through 2020. The abstract does not provide the exact AAMR values or APC estimates in this summary, but the directional change is clear: the latter years of the study were characterized by worsening rather than improving mortality.
That trend is notable because it contrasts with the expectation that advances in neurocritical care, EEG availability, standardized emergency protocols, and broader antiseizure medication options should reduce mortality over time. The study therefore suggests that gains in treatment may have been offset by other forces, including older and more medically complex patient populations, persistent disparities, and changing epidemiology of precipitating conditions.
Age-related burden
Adults aged 65 years and older had the highest crude mortality rates. This aligns with everyday clinical experience. Older adults are more likely to develop SE from acute symptomatic causes such as ischemic stroke, intracerebral hemorrhage, neurodegenerative disease, systemic infection, renal or hepatic dysfunction, medication toxicity, and metabolic encephalopathy. They are also more vulnerable to respiratory compromise, prolonged encephalopathy, and withdrawal of life-sustaining treatment in the context of severe comorbidity.
These findings reinforce the need for age-specific preventive and management strategies. In practical terms, this includes aggressive prevention and treatment of stroke and CNS infections, early recognition of nonconvulsive SE in hospitalized older adults with altered mental status, and careful medication reconciliation to avoid withdrawal-related or drug-induced seizures.
Sex differences
Men had higher age-adjusted mortality rates than women. The study does not establish why, but several plausible mechanisms exist. Men may have different distributions of underlying etiologies, including higher rates of alcohol-related seizures, traumatic brain injury, vascular risk factors, and delayed healthcare engagement. Biological and social determinants likely interact. Regardless of mechanism, the signal is consistent enough to merit attention in both risk stratification and public health messaging.
Racial and ethnic disparities
Among racial and ethnic groups, Non-Hispanic Black individuals had both the highest age-adjusted mortality rate and the greatest rise in mortality over time. Non-Hispanic White individuals and Hispanic or Latino populations followed. This is among the most important findings of the study because it points beyond neurology alone to structural inequity in health outcomes.
Race in mortality datasets is a social, not biological, variable. Therefore, the excess burden in Non-Hispanic Black populations should not be interpreted as intrinsic susceptibility. More likely contributors include differential exposure to upstream risk factors such as hypertension, stroke, chronic kidney disease, and barriers to preventive and acute care; variation in insurance and specialty access; prehospital delays; differences in hospital resources; and broader structural determinants including neighborhood deprivation and health system fragmentation.
For clinicians and health systems, the implication is direct: reducing SE mortality will require more than refining ICU treatment protocols. It will also require closing gaps in cerebrovascular prevention, emergency response, neurology access, and continuity of epilepsy care.
Regional variation
The Southern United States had the highest age-adjusted mortality rate among geographic regions. This finding is epidemiologically plausible. The South has long carried a disproportionate burden of stroke, cardiovascular disease, poverty-related health disadvantage, and uneven access to specialty care. Those factors overlap strongly with the conditions that predispose adults to SE and worsen outcomes after neurologic emergencies.
Regional variation also raises systems-level questions. Are there differences in emergency medical services response, EEG access, neurocritical care bed availability, timeliness of benzodiazepine administration, transfer patterns, or coding practices? The current study cannot answer those questions, but it identifies where such investigations should be prioritized.
Clinical Interpretation and Public Health Relevance
This study is best read as a warning signal. SE remains a high-mortality neurologic emergency, and at the population level the U.S. is not moving in the right direction. The post-2007 increase in mortality suggests that contemporary practice improvements have not translated into better national mortality outcomes, at least not enough to overcome worsening baseline risk in vulnerable populations.
Several interpretations deserve consideration. First, part of the increase may reflect improved recognition and documentation of SE on death certificates, especially with wider use of continuous EEG and greater awareness of nonconvulsive SE. Second, the burden of underlying conditions strongly linked to SE mortality may have increased over time, particularly in older adults. Third, disparities in treatment access and quality may persist across race and region. These explanations are not mutually exclusive.
For frontline clinicians, the study supports a more deliberate approach to high-risk phenotypes. Older adults with acute neurologic or metabolic insults require rapid screening for electroclinical seizures. Hospitals serving high-burden regions and underserved populations may need explicit SE pathways that shorten time to first-line therapy, facilitate urgent EEG, and standardize escalation to second-line and anesthetic treatment when indicated.
For health systems and policymakers, the findings argue for integrating SE into broader neurologic emergency frameworks, particularly stroke systems of care. Because many fatal SE episodes are precipitated by acute symptomatic insults, improvements in stroke prevention, sepsis care, substance-use treatment, renal disease management, and medication access may reduce SE mortality indirectly but meaningfully.
The study also has implications for equity-focused quality improvement. If Non-Hispanic Black adults experience both the highest mortality and the steepest increase over time, then quality metrics should be examined through a disparities lens. Potential indicators include time to benzodiazepine administration, time to EEG, ICU transfer delays, discharge access to antiseizure medications, outpatient neurology follow-up, and rehospitalization rates.
Strengths and Limitations
The strengths of the study include its national scope, long observation period, and use of standardized mortality surveillance methods. By combining age-adjusted analyses with subgroup stratification, the authors provide a useful high-level view of where the burden is concentrated and how it has evolved over two decades.
The main limitations arise from the nature of death certificate data. Cause-of-death coding may be inaccurate or incomplete, and the designation of SE as a contributing or underlying cause may vary by clinician, institution, and era. The dataset cannot distinguish convulsive from nonconvulsive SE, refractory from nonrefractory disease, or inpatient-acquired from community-onset events. It also lacks important clinical variables such as etiology, antiseizure treatment, EEG findings, severity of systemic illness, ICU use, socioeconomic status, and insurance status.
These limitations matter because mortality in SE is tightly linked to etiology. A patient with SE related to anoxic brain injury has a profoundly different prognosis from a patient with medication nonadherence and otherwise preserved health. Without etiologic granularity, the study can identify disparities but cannot fully explain them.
Another interpretive caution is the use of mortality rather than incidence-adjusted case fatality. Rising mortality could reflect more SE events, greater lethality per event, or both. Future work should therefore pair national mortality surveillance with hospitalization, claims, registry, or electronic health record data to disentangle incidence, treatment patterns, and case fatality across subgroups.
Conclusion
This national analysis shows that mortality related to status epilepticus in U.S. adults has increased since 2007, with the heaviest burden borne by older adults, men, Non-Hispanic Black populations, and residents of the South. Most deaths occurred in medical facilities, indicating that hospital-based care alone has not eliminated the lethality of this condition.
The clinical message is clear: status epilepticus should be treated not only as an acute neurologic emergency but also as a marker of broader vulnerability at the intersection of aging, comorbidity, and health inequity. Efforts to reduce mortality will likely need to combine faster evidence-based acute treatment with upstream prevention of precipitating illnesses and targeted strategies to address racial and regional disparities. For clinicians, researchers, and policymakers, this study provides a compelling rationale to make SE outcomes a more visible national quality priority.
Funding and Registration
The abstract provided does not report funding information or a ClinicalTrials.gov registration number. As a retrospective analysis of a public mortality database, trial registration would generally not be expected.
References
1. Nadeem ZA, Kashif MAB, Nadeem A, Fatima U, Zulfiqar K, Kareem R, Farooq M, Johar A, Chaychi MTM, Ahmed MK. Temporal Trends and Regional Variations in Mortality of Adults With Status Epilepticus in the United States: A Retrospective Study From 1999 to 2020. Neurology. 2026-04-30;106(10):e214939. PMID: 42060883.
2. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus: Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
3. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM, Vespa PM. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
4. Claassen J, Jette N, Chum F, Green R, Schmidt M, Choi H, Hirsch LJ, Connolly ES, Emerson RG, Mayer SA. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology. 2007;69(13):1356-1365.
5. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615-624.
